Last reviewed · How we verify

PF-06940434 — Competitive Intelligence Brief

PF-06940434 (pf-06940434) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2. Area: Oncology.

discontinued PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2 Oncology Live · refreshed every 30 min

Target snapshot

PF-06940434 (pf-06940434) — Pfizer Inc.. PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PF-06940434 TARGET pf-06940434 Pfizer Inc. discontinued PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2 class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-06940434 — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-06940434. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: